The EMA’s CHMP has adopted a positive opinion on the approval of Orserdu for postmenopausal women & men with ER+ HER2- LA or metastatic breast cancer with an activating ESR1 mutation who have disease progression following one line of endocrine therapy
The opinion was based on the P-III (EMERALD) trial results evaluating elacestrant as monotx. vs SoC in 478 patients which showed a significant PFS, m-PFS (3.8 vs 1.9mos.) in the group of patients whose tumors had ESR1 mutations, 45% reduction in risk of progression or death
In a post hoc subgroup analysis, the duration of prior CDK4/6i treatment was associated with longer PFS on elacestrant, m-PFS (8.6 vs 1.9mos.) for patients with ESR1 mutations treated with CDK4/6i for ≥12mos., 59% reduction in risk of progression or death
Ref: PR Newswire | Image: Menarini
Related News:- Context Therapeutics’ Clinical Partner Stemline Therapeutics Receives the US FDA’s Approval of Orserdu (elacestrant) for ER+, HER2-, ESR1-Mutated Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
